Shares of biotech micro cap Equillium <a href="https://www.marketwatch.com/investing/stock/eq?utm_source=in_materials">soared</a> 33% yesterday, Thursday, February 6, although some of the gains have been lost before the opening bell today. The company <a href="https://www.equilliumbio.com/investors/press-releases/news-details/2025/Equillium-Announces-Positive-Data-from-Phase-2-Study-Evaluating-Itolizumab-in-Patients-with-Moderate-to-Severe-Ulcerative-Colitis/default.aspx?utm_source=in_materials">announced</a> that its drug for ulcerative colitis, which it is testing together with Indian pharmaceutical giant Biocon, has shown results that are no worse than the standard of care for the disease. The therapy is Equillium’s lead candidate to get to market.

Announced successful drug trials boost micro cap Equillium by 33%

Quotes on the small-cap telemedicine platform Teladoc Health <a href="https://finance.yahoo.com/quote/TDOC/?utm_source=in_materials">surged</a> almost 6% yesterday, Wednesday, February 5, before extending the gains in premarket trading today. The trigger was an announcement that the company had signed an agreement to acquire Catapult Health, which provides at-home diagnostic kits. The deal follows a challenging period that saw the market valuation of Teladoc shrink more than 18-fold from its pandemic peak.

Virtual healthcare provider Teladoc to acquire competitor; shares jump 6%

Shares of Viemed Healthcare, a company with a market capitalization of almost $355 million that provides in-home respiratory support, surged almost 16% in after-hours trading on Wednesday, November 6. The gains were attributable to third-quarter financial results, which featured record- and guidance-beating revenue.

#Healthcare: 3

Announced successful drug trials boost micro cap Equillium by 33%

Virtual healthcare provider Teladoc to acquire competitor; shares jump 6%

Home medical services provider Viemed soars on third-quarter financials